Last year AstraZeneca's MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. Bahija Jallal, head of R&D, tells FierceBiotech there will be no letup in talent scouting: "If we do as little or more than last year, I would be happy."
In another early-stage bet, AstraZeneca's MedImmune unit acquired the biotech AlphaCore Pharma. The deal comes as AstraZeneca ($AZN) reboots a floundering R&D effort and adds a recombinant LCAT enzyme therapy from AlphaCore that could combat cardiovascular disease.
In another early-stage bet, AstraZeneca's MedImmune unit acquired the biotech AlphaCore Pharma. The deal comes as AstraZeneca reboots a floundering R&D effort and adds a recombinant LCAT enzyme therapy from AlphaCore that could combat cardiovascular disease.
The Facility of the Year Awards recognizes winners from the U.S., Ireland, the U.K. and Switzerland, including three vaccine facilities.
When the AstraZeneca elevated MedImmune's Bahija Jallal to head up biologics development, it gutted the unit's commercial and manufacturing operations.
The big shakeup under way at AstraZeneca under new CEO Pascal Soriot has hit home at MedImmune. Peter Greenleaf is out as president of the Gaithersburg, MD-based biotech division and Bahija Jallal, now a member of an R&D troika on AstraZeneca's executive group in the wake of Martin Mackay's ouster, is stepping up to the top spot.
As Big Pharma looks to tap the burgeoning drug market in China, companies are realizing they can't bulldoze in with U.S.-approved drugs and expect a red carpet. Instead, firms such as Vertex and AstraZeneca's MedImmune are looking to partner up with local expertise to speed their way to capitalization.
Researchers at the University of Minnesota's Center for Infectious Disease Research and Policy claim current influenza vaccines offer less protection against the infectious disease than previously thought, and better ones are necessary.
Cancer immunotherapy research has once again topped the R&D charts as one of the hottest fields in biotech. And now MedImmune, the biologics arm of AstraZeneca, has teamed up with some prestigious research teams to come up with some revved up combo therapies using a few of their most promising antibodies.
As flu season approaches, vaccines companies are working against the odds to market their influenza vaccines. Last year, the overall U.S. vaccination rate was about 42%--a far cry from the target rates of 80% for people ages 6 months to 65 years and 90% for those older than 65.